Press release
Dry Age-Related Macular Degeneration Pipeline Appears Robust with 58+ Key Pharma Companies Actively Working in the Therapeutics Segment
In the Dry Age-Related Macular Degeneration Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
• DelveInsight's Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 58+ active players working to develop 64+ pipeline therapies.
• The leading Dry Age-related Macular Degeneration Pipeline Companies includes Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others.
• Promising Dry Age-related Macular Degeneration Pipeline Therapies includes ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
• The Dry Age-Related Macular Degeneration companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-related Macular Degeneration R&D. The Dry Age-Related Macular Degeneration pipeline therapies under development are focused on novel approaches to treat/improve Dry Age-related Macular Degeneration.
Explore more information on the latest breakthroughs in the Dry Age-Related Macular Degeneration Treatment Landscape of the report and Dry Age-Related Macular Degeneration Pipeline Outlook @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Dry Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. "Age-related" means that it mainly occurs with elderly adults, while "Macular" means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago.
Recent Developmental Activities in the Dry Age-Related Macular Degeneration Treatment Landscape
• In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company's second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
• In June 2021, Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property.
• The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
• In January 2021 Gemini Therapeutics announced that GEM103, the company's investigational treatment for dry AMD, had been granted Fast Track designation by the FDA.
• In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
• In December 2020, Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC's investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
• On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company's Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.
Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Pipeline Therapies, visit Dry Age-Related Macular Degeneration Treatment Landscape @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Dry Age-Related Macular Degeneration Emerging Drugs Profile
• ALK-001: Alkeus Pharmaceuticals
ALK-001 is once-a-day oral drug candidate currently being tested for the treatment of geographic atrophy (advanced form of dry AMD) and Stargardt disease. Toxic vitamin A aggregates called "dimers" are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers.
• Elamipretide: Stealth BioTherapeutics
Elamipretide (Stealth BioTherapeutics) is a novel tetrapeptide drug currently in development for both common and orphan diseases that involve dysfunction of the mitochondria, the cellular organelles that generates chemical energy in the form of adenosine triphosphate (ATP). At the cellular level, mitochondrial dysfunction causes loss of ATP production, increased levels of reactive oxygen species (eg, superoxide), calcium dysregulation, and, if prolonged, cell death.
Elamipretide, given as systemic injection, penetrates tissues and cells and enters the mitochondria, where it reverses mitochondrial dysfunction (improved ATP production, restored mitochondrial membrane potential, normal calcium flux, and reduced superoxide generation).
• CPCB-RPE1: Regenerative Patch Technologies
Regenerative Patch Technologies has developed composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane.
• AAV.sFH: Aevitas Therapeutics
AAV.sFH, is an investigational drug being developed by Aevitas Therapeutics. Aevitas advances AAV gene therapies of short-form human factor H (sFH) to restore homeostasis in disorders of complement dysregulation: dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS) and other disorders. sFH restored complement regulation in eyes of FH knockout mice with subretinal administration.
Supraphysiological expression of sFH with subretinal administration was shown in non-human primate eye. Good vector genome transfer to ocular target tissues with intravitreal administration was demonstrated in Yorkshire pigs. Transgene product sFH was present in all eye compartments with potentially clinically relevant FH levels in the porcine eye. Currently, the drug is in Preclinical stage of development for the treatment of Dry AMD.
Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment
There are approx. 58+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
Get to know more information about the Dry Age-Related Macular Degeneration Emerging Drugs and Dry Age-Related Macular Degeneration Companies of the report @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Dry Age-Related Macular Degeneration Pipeline Report
• Coverage- Global
• Dry Age-related Macular Degeneration Companies- Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others.
• Dry Age-related Macular Degeneration Pipeline Therapies- ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
• Dry Age-related Macular Degeneration Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Dry Age-Related Macular Degeneration Market Drivers and Dry Age-Related Macular Degeneration Market Barriers, click here Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Dry Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Age-related Macular Degeneration- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Abicipar pegol: Molecular Partners
9. Late Stage Products (Phase III)
10. ALK-001: Alkeus Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Elamipretide: Stealth BioTherapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. AAV.sFH: Aevitas Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Dry Age-related Macular Degeneration Key Companies
23. Dry Age-related Macular Degeneration Key Products
24. Dry Age-related Macular Degeneration- Unmet Needs
25. Dry Age-related Macular Degeneration- Market Drivers and Barriers
26. Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
27. Dry Age-related Macular Degeneration Analyst Views
28. Dry Age-related Macular Degeneration Key Companies
29. Appendix
Got Queries? Find out the related information on Dry Age-Related Macular Degeneration Mergers and acquisitions, Dry Age-Related Macular Degeneration Licensing Activities, and Click here for Dry Age-Related Macular Degeneration Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-Related Macular Degeneration Pipeline Appears Robust with 58+ Key Pharma Companies Actively Working in the Therapeutics Segment here
News-ID: 2967067 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Dry
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
Dry Screw Vacuum Pumps
Swam Dry vacuum pumps are the latest development in the vacuum pump industry. They offer a number of advantages over traditional vacuum pump designs. Best process gas blowers. There is “NO OIL / NO WATER” contact with the process vapours, which is why they are considered extremely environmentally friendly.
Visit us for more info - http://swamatics.com/ProductDetails.aspx?prod=Process%20Gas%20Blowers/Gas%20Boosters
The definition of a dry vacuum pump is a pump that does not use any…
